readthroughSign in
Nov 16, 2026Quarterly update

AEON Biopharma gets FDA Type 2b feedback on ABP-450 biosimilar path, files CMAP IND

AEON says FDA input and new analytical data support a combined approach to proving ABP-450 is biosimilar to BOTOX, with a pharmacodynamic study planned for Q1 2027 and cash into Q2 2027.

AEON Biopharma reported third quarter 2026 results on November 16, 2026, and said it had received official minutes from ABP-450's Biosimilar Biological Product Development Type 2b meeting with the FDA1. The company said the FDA agreed in principle with AEON's two-stage design for a comparative pharmacodynamic study using compound muscle action potential measurement in the extensor digitorum brevis muscle, consisting of an initial dose-finding stage followed by a comparative PD evaluation1.

AEON said it submitted ABP-450's IND to the FDA for a comparative PD study utilizing CMAP measurements1, with expected study initiation in the first quarter of 20271. On prior clinical evidence, the FDA indicated that studies conducted by Daewoong Pharmaceutical across several indications, including blepharospasm, upper limb spasticity, glabellar lines, and lateral canthal lines, can be submitted for consideration as supportive evidence, subject to appropriate scientific bridging1. For chronic migraine, the FDA invited the Company to provide analyses supporting the rationale for the outcome of the previously conducted Phase 2 study for the prevention of migraine headache, which the Company intends to complete and provide to the FDA as part of its 351(k) Biologics License Application submission1.

On analytics, AEON said it improved peptide-mapping methods and increased the coverage of the core botulinum neurotoxin primary sequence from approximately 93% to 98%, with 100% amino acid identity across all regions analyzed1. The company also reported pilot forced degradation results in which, under thermal stress, both ABP-450 and BOTOX lost potency at comparable rates, and under oxidative stress, methionine sites were modified in both molecules in a similar dose-dependent pattern1, with a multi-lot forced degradation comparability study planned for the first half of 20271.

On financing, AEON said it had received approximately $6.2 million in gross proceeds from exercises of two-year milestone warrants as of November 16, 20261. The Company reported cash and cash equivalents of $11.4 million as of September 30, 2026, not including the $6.2 million in warrant proceeds received in the fourth quarter, and said this is expected to fund operations into the second quarter of 20271.

Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.